Risperidone: A new, novel (and better?) antipsychotic

Psychiatric Annals

Volumn 26, Issue 2, 1996, Pages 78-87

  Davis, John M ^a   Janicak, Philip G ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Psychiatric Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030532233     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19960201-08     Document Type: Article

References (63)

1. 2 antagonistic properties. J Pharmacol Exp Ther. 1988; 244:685-693.
2. Leysen JE, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988; 247:661-670.
3. 123HBZM single photon emission tomography (SPET) study. Psychopharmacology. 1995; 117:55-61.
4. Megens AAHP, Awouters FHL, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology. 1994; 114:9-23.
5. 2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study. Eur Neuropsychopharmacol. 1995; 5:19-25.
6. Wiesel F-A, Nordstrom A-L, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology. 1994; 114:31-38.
7. Gelders Y, Ceulemans O, Hoppenbrouwers ML, Reyntjens A, Mesotten F. Ritanserin, a selected serotonin antagonist in chronic schizophrenia. IV World Congress of Psychiatry; Philadelphia, PA; 1985:338.
8. 2 antagonist ritanserin. Psychopharmacol Bull. 1990; 26:373-376.
9. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 1993; 110:265-272.
10. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995; 15(suppl 1):19-23.
11. Schotte A, Janssen PFM, Bonaventure P, Lemmens P, Leysen JE. In vivo receptor occupancy in rat brain by novel and reference antipsychotic drugs. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
12. Roose K, Gelders HG, Heylen S. Risperidone in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg. 1988; 88:233-241.
13. 2 antagonist risperidone (R 64766) in the treatment of chronic psychoses: an open dose finding study. Schizophr Res. 1989; 2:411-415.
14. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology. 1989; 99:445-449.
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-835.
16. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13:25-40.
17. Musser WS, Kirisci L. Critique of the Canadian multicenter placebo-controlled study of risperidone and haloperidol. J Clin Psychopharmacol. 1995; 15:226-228.
18. Müller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol. 1992; 15(suppl 1):90A-91A. Abstract.
19. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992; 28:213-218.
20. Hoyberg O, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993; 88:395-402.
21. Claus A, Bollen J, De Cuyper H, Heylen LE. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992; 85:295-305.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1979; 22:719-748.
23. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, FL: Academic Press; 1985.
24. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins; 1993.
25. Jones BD, Purdon SE, Labelle A, Finlayson R. Risperidone treatment for severe negative symptoms. Can J Psychiatry. 1994; 39:381.
26. Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single blind crossover study versus placebo. Current Therapeutic Research. 1989; 46:876-883.
27. Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 1994; 18:129-137.
28. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 1995; 15(suppl 1):45-51.
29. Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H. A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
30. Horne RL, Miller F. Outcome in patients switched from clozapine to risperidone. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
31. Abuzzahab FS, Gillund JM. Clozapine and risperidone in schizophrenia. 33rd Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; December 12-16, 1994. Poster.
32. McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry. 1995; 28:61-63.
33. Mertens C. Long-term treatment of chronic schizophrenic patients with risperidone. In: Kane JM, ed. Risperidone: Major Progress in Antipsychotic Treatment. Oxford, England: Oxford Clinical Communications; 1991:44-48.
34. De Wilde J, Dierick M. Long term treatment of schizophrenic patients with risperidone. Biol Psychiatry. 1991; 29:675S.
35. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. Risperidone effective and safe in long-term treatment of chronic schizophrenics. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25,1995. Abstract.
36. Evans E. Risperidone in institutionalized psychotic patients unresponsive to conventional antipsychotic agents. American Psychiatric Association, New Research and Abstracts NR262:26; 1995.
37. Khreis IY, Slaughter JR. Risperidone for primary psychogenic polydipsia. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
38. Horne RL, Miller F. Use of risperidone in a private psychiatric practice. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
39. Hillert A, Maier W, Wetzel H, Benkert O. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry. 1992; 25:213-217.
40. Tohen M, Zarate CA Jr, Centorrino F, et al. Risperidone in the treatment of mania. 33rd Annual Meeting of the American College of Neuropsychopharmacology; San Juan, Puerto Rico; December 1994. Poster.
41. Ghaemi SN, Sachs GS, Baldassano C, Truman C. Management of bipolar disorder with adjunctive risperidone: response to open treatment. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
42. Dwight MM, Keck PE, Stanton SP, Strakowski SM, McElroy SL. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet. 1994; 334:554-555.
43. Vanden Borre R, Vermote R, Buttiens M, et al. Risperidone as add-on therapy in behavioral disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1993; 87:167-171.
44. Furmaga KM, DeLeon OA, Sinha SB, Jobe TH. Risperidone in the treatment of patients with refractory psychosis due to brain injury. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
45. Aronson SM, Lingham V, Hasanat KA. Risperidone in geropsychiatry: review of early experience in two public hospitals. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
46. Davidson M, Berman I, Keefe RS, Duwi K, Pontecorvo M. Risperidone in elderly schizophrenic patients. Schizophr Res. 1994; 11(2 special issue):197.
47. Goldberg RJ. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
48. Gilmer W, Ferrando S, Jong M, Goldman J. Risperidone in the treatment of psychiatric symptoms in patients with AIDS. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
49. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet. 1994; 344:1029-1030.
50. van der Linden C, Bruggeman R, van Woerkom TCAM. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994; 9:687-688.
51. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette's syndrome. Lancet. 1994; 344:1577-1578.
52. Meco G, Alessandria A, Bonifate P, Geusteme P. Risperidone for hallucinations in levodopa Parkinson's disease patients. Lancet. 1994; 343:1370-1371.
53. Rerrier MA, Andrews H, Durson SM. A comparative trial use of sulpiride and risperidone in Huntington's disease. J Psychopharmacol 1994; 116:29. Abstract.
54. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol. 1994; 14:430-431.
55. Shriqui CL, Nobecourt P, Rousseau E, Arnott W. Clinical efficacy of risperidone in a patient with severe tardive dyskinesia. Neuropsychopharmacology. 1994; 10(suppl 2):242. Abstract.
56. Tomsic J, Chatt PL, Chandarana P. Neuroleptic malignant syndrome caused by risperidone. Canadian Journal of Hospital Pharmacy. 1994; 47:85.
57. Lee H, Ryan J, Mullett G, Lawlor BA. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Human Psychopharmacology. 1994; 9:303-305.
58. Aaby P, Knudsen K, Simondon F, et al. Risperidone-induced neuroleptic malignant syndrome. Lancet. 1994; 344:1228-1229.
59. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in a young patient. Lancet. 1994; 344:1705.
60. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet. 1994; 344(8931):1228-1229.
61. Heykants J, Huang M-L, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. In: Risperidone: New Horizons for the Schizophrenic Patient. Proceedings of a Satellite Symposium at the 9th World Congress of Psychiatry; Rio de Janeiro, Brazil; June 6-12, 1993.
62. Jones BD, Lemmens P. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. 148th Annual Meeting of the American Psychiatric Association; Miami, FL; May 20-25, 1995. Abstract.
63. Addington D, Jones B, Bloom D, Chouinard G, Remington G, Allbright P. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993; 15:917-926.